Literature DB >> 9552226

The role of the fecal stream in Crohn's disease: an historical and analytic review.

H D Janowitz1, E C Croen, D B Sachar.   

Abstract

Since 1939, a series of clinical reports and laboratory investigations have suggested that the intestinal fecal stream may play a significant part in the pathogenesis of Crohn's disease (CD). The beneficial effect of exclusion of the stream by ileostomy was followed by improvement in patients with CD of the ileum and colon despite little change in the histopathology of the excluded loop, even to the point of allowing restoration of intestinal continuity in some patients. End ileostomy lowers the risk of recurrence of CD compared with anastomotic operations. Ileostomy effluent can reactivate the clinical activity of quiescent bypassed bowel and some of its biochemical processes, and may be related to an ultrafilterable constituent > 5 microns. Experimental models of inflammatory bowel disorders in immunologically altered rodents (transgenic, knockout, or spontaneous) require the presence of normal luminal bacteria, especially of the Bacteroides species, and respond to antibiotic (metronidazole) therapy. Thus, many but not all of the well-recognized clinical features of CD are compatible with a pathogenetic role of the fecal stream. Although difficult to quantitate, this concept opens the way to a variety of testable research lines, and allows some speculation regarding its clinical implications.

Entities:  

Mesh:

Year:  1998        PMID: 9552226     DOI: 10.1097/00054725-199802000-00006

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  28 in total

1.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 3.  Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence.

Authors:  J P Achkar; B Shen
Journal:  Curr Gastroenterol Rep       Date:  2001-12

Review 4.  Probiotics and inflammatory bowel disease.

Authors:  Daisy Jonkers; Reinhold Stockbrügger
Journal:  J R Soc Med       Date:  2003-04       Impact factor: 5.344

Review 5.  Intestinal microflora as a therapeutic target in inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Atsushi Toyonaga; Michio Sata
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

6.  Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells.

Authors:  Ulf Helwig; Karen M Lammers; Fernando Rizzello; Patricia Brigidi; Verena Rohleder; Elisabetta Caramelli; Paolo Gionchetti; Juergen Schrezenmeir; Ulrich R Foelsch; Stefan Schreiber; Massimo Campieri
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

Review 7.  Do probiotics have a therapeutic role in gastroenterology?

Authors:  Jimmy K Limdi; Catherine O'Neill; John McLaughlin
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

Review 8.  Managing medical complications and recurrence after surgery for Crohn's disease.

Authors:  Bo Shen
Journal:  Curr Gastroenterol Rep       Date:  2008-12

Review 9.  Triggers and drivers of autoimmunity: lessons from coeliac disease.

Authors:  Ludvig M Sollid; Bana Jabri
Journal:  Nat Rev Immunol       Date:  2013-03-15       Impact factor: 53.106

10.  A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease.

Authors:  Andreas M Petersen; Eva M Nielsen; Eva Litrup; Jørn Brynskov; Hengameh Mirsepasi; Karen A Krogfelt
Journal:  BMC Microbiol       Date:  2009-08-20       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.